NCT05918614View on ClinicalTrials.gov

A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 28, 2014

Primary Completion Date

June 7, 2014

Study Completion Date

June 7, 2014

Conditions

Immune System Disorder (Healthy Volunteer)

Interventions

DRUG

Belumosudil mesylate

Pharmaceutical form: capsule; Route of administration: oral

DRUG

Placebo

Pharmaceutical form: capsule; Route of administration: oral

Trial Locations (1)

14202

Investigational site, Buffalo

All Listed Sponsors

lead

Kadmon, a Sanofi Company

INDUSTRY

NCT05918614 - A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjects | Biotech Hunter | Biotech Hunter